Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

• Status: Completed
• Trial end date: 2019-11-23
• Target enrollment: 0
• Participant gender: All

Summary

Investigators are doing this study to determine which of four imaging techniques:

Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michael C Roarke, MD
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator

• Patients who have undergone standard of care workup

• 300 pounds or less

• Can provide informed consent

• Scheduled for a clinically indicated F-18 FDG PET scan

• English speaking

Exclusion Criteria:

• Pregnant, breast feeding

• Concurrent active non-multiple myeloma malignancy

• Contraindication to PET MRI

• Previous Type I or Type II Diabetes mellitus or a fasting blood glucose >150 mg/dl